GlassScriptPhysician profile
Laura Villafane
NPI 1831615178
$8,114.70
in general payments reported to CMS, 2019-2025
31 companies · $1,527 in 2025
The $1,527 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $945 · 2022: $2,056 · 2023: $1,518 · 2024: $2,068 · 2025: $1,527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,953 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,953.40 |
| Education | $159.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,484.43 | 2021-2025 | |
| Allergan, INC. | $736.29 | 2022 | |
| Janssen Biotech, INC. | $603.07 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $598.76 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Incyte Corporation | $559.79 | 2021-2025 | Opzelura |
| Genzyme Corporation | $409.99 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $394.27 | 2022-2024 | Sotyktu |
| Dermavant Sciences, INC. | $351.48 | 2023-2024 | Vtama |
| Pfizer INC. | $336.26 | 2021-2024 | |
| Leo Pharma INC. | $311.59 | 2024-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $294.13 | 2021-2025 | Taltz, Ebglyss |
| Amgen INC. | $259.62 | 2021-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $236.41 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $224.02 | 2021-2025 | Dupixent, Libtayo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $221.68 | 2021-2025 | Jublia, Arazlo, Cabtreo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $201.63 | 2023-2025 | Zoryve |
| Ucb, INC. | $189.28 | 2021-2025 | Bimzelx |
| Almirall LLC | $130.11 | 2022-2025 | Seysara |
| Galderma Laboratories, L.P. | $101.22 | 2022-2025 | Aklief |
| Journey Medical Corporation | $99.39 | 2022-2025 | |
| Organon LLC | $70.54 | 2025 | Vtama |
| Sebela Pharmaceuticals INC. | $49.39 | 2022-2023 | Naftin |
| Vyne Pharmaceuticals INC. | $42.34 | 2021 | |
| Nabriva Therapeutics, Plc | $37.00 | 2022 | |
| Mayne Pharma Commercial LLC | $34.05 | 2023 | |
| Helsinn Therapeutics (U.S.), INC. | $33.31 | 2022 | |
| Medtronic, INC. | $28.57 | 2024 | Closurefast |
| Lnhc, INC | $23.74 | 2025 | Zelsuvmi |
| Ani Pharmaceuticals, INC. | $21.21 | 2025 | Oxistat |
| Tempus Ai, INC | $16.29 | 2024 | Merlin Test |
| Paratek Pharmaceuticals, INC. | $14.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Villafane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.